Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Avecho Biotechnology Ord Shs V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Comment by rusty777on Feb 26, 2019 1:03pm
44 Views
Post# 29414985

RE:still holding this stock

RE:still holding this stockHi Cool

I would sorely like you to be correct - I am underwater on this one until it is in the mid $10.00 - however, it seems that the more they make the more they spend.  A recent summary by Zack's (https://s1.q4cdn.com/460208960/files/News/2019/Zacks_SCR_Research_02072019_DSKE_Ralston.pdf) suggests that even though they are increasing their income by over 90% they are estimated to lose anywhere from 20 - 41 cents per share - hard to fathom how they manage to do this - especially given the cost of fuel over the past few months but, sadly, that is the expectation.  I am not sure how other analysts consider a 12 month valuation of over $12.00 for a company that seems completely unable to turn a profit.  At the end of the day, increasing earnings is meaningless if your expenses are increasing at a greater rate.

Tried talking with IR - unfortunately, he spent more time telling me how wonderful everything was and trying to snow me with bafflegab rather than answering why costs continue to outstrip earnings by such an extent......

March 8th will be interesting.

Rusty
<< Previous
Bullboard Posts
Next >>